• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    CVS Health appoints Michael F. Mahoney to its Board of Directors

    9/21/23 6:45:00 AM ET
    $BSX
    $CVS
    Medical/Dental Instruments
    Health Care
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $BSX alert in real time by email

    WOONSOCKET, R.I., Sept. 21, 2023 /PRNewswire/ -- CVS Health Corporation (NYSE:CVS) has appointed Michael F. Mahoney, Chairman and CEO of Boston Scientific Corporation (NYSE:BSX), a global medical technology leader, to serve on the Board of Directors (the "Board") of CVS Health, effective November 1.

    CVS Health (PRNewsFoto/CVS Health)

    "Mike's focus throughout his career – to drive improvements in health outcomes and increase access to care – align with our mission at CVS Health," said CVS Health President and CEO Karen S. Lynch. "Adding a well-respected health care leader to our Board demonstrates our continued focus on strengthening our engagement with consumers to improve their health and well-being."

    Mahoney became the CEO of Boston Scientific Corporation in 2012 and became Chairman of the company's Board of Directors in 2016. With more than 45,000 global employees, Boston Scientific reaches over 33 million patients each year, providing a range of technologies and solutions that span cardiovascular interventions, structural heart, electrophysiology, endoscopy, neuromodulation, urology, and women's health.

    "We're extremely pleased to have Mike join the Board," said Roger N. Farah, Independent Chair of the Board of CVS Health. "His knowledge and insight will be a tremendous asset, as will his background in leading the development of innovative solutions for patients."

    Mahoney's career spans more than 25 years of success building market-leading medical device, capital equipment and health care IT businesses. Prior to Boston Scientific, he served as Worldwide Chairman of the Medical Devices and Diagnostics division of Johnson & Johnson. Mahoney previously was President and CEO of Global Healthcare Exchange, a leading medical supply chain solutions company. For the first 12 years of his career, he advanced through a series of leadership roles at General Electric Medical Systems, including as General Manager of its Healthcare Information Technology business.

    "CVS Health and Boston Scientific share many common goals, with a primary focus on making a real difference for the people and patients we serve," Mahoney said. "I hope that my experience within the health care industry will help me work with the Board and the management team to support and advance CVS Health's strategy."

    Mahoney serves on the Board of the Boys & Girls Club of Boston and as the chair of the Board of Governors of the Boston College Chief Executives Club. He previously served on the Board of Directors of Baxter International Inc., a multinational health care company. He earned his B.B.A. in Finance from the University of Iowa and his M.B.A. from Wake Forest University. He is married and has three children.

    About CVS Health

    CVS Health® is the leading health solutions company, delivering care like no one else can. We reach more people and improve the health of communities across America through our local presence, digital channels and over 300,000 dedicated colleagues – including more than 40,000 physicians, pharmacists, nurses and nurse practitioners. Wherever and whenever people need us, we help them with their health – whether that's managing chronic diseases, staying compliant with their medications or accessing affordable health and wellness services in the most convenient ways. We help people navigate the health care system – and their personal health care – by improving access, lowering costs and being a trusted partner for every meaningful moment of health. And we do it all with heart, each and every day. Follow @CVSHealth on social media.

    Media contact

    Ethan Slavin

    860-273-6095

    [email protected]

    Investor contact

    Larry McGrath

    800-201-0938

    [email protected] 

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cvs-health-appoints-michael-f-mahoney-to-its-board-of-directors-301934025.html

    SOURCE CVS Health

    Get the next $BSX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BSX
    $CVS

    CompanyDatePrice TargetRatingAnalyst
    CVS Health Corporation
    $CVS
    10/14/2025$91.00Buy
    Goldman
    Boston Scientific Corporation
    $BSX
    10/3/2025Buy → Hold
    Erste Group
    Boston Scientific Corporation
    $BSX
    9/8/2025$125.00Perform → Outperform
    Oppenheimer
    CVS Health Corporation
    $CVS
    8/18/2025$79.00Neutral → Buy
    UBS
    CVS Health Corporation
    $CVS
    8/14/2025$82.00Neutral → Outperform
    Robert W. Baird
    Boston Scientific Corporation
    $BSX
    6/16/2025$118.00Outperform
    Leerink Partners
    Boston Scientific Corporation
    $BSX
    4/16/2025$113.00Hold → Buy
    Needham
    CVS Health Corporation
    $CVS
    2/13/2025$55.00 → $75.00Market Perform → Outperform
    Leerink Partners
    More analyst ratings

    $BSX
    $CVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on CVS Health with a new price target

    Goldman initiated coverage of CVS Health with a rating of Buy and set a new price target of $91.00

    10/14/25 8:48:20 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Boston Scientific downgraded by Erste Group

    Erste Group downgraded Boston Scientific from Buy to Hold

    10/3/25 8:32:04 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Boston Scientific upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Boston Scientific from Perform to Outperform and set a new price target of $125.00

    9/8/25 8:36:41 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    $CVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CathVision Announces Appointment of Eric Thepaut as Independent Chairman of the Board and Releases ECGenius® System Version 3.5

    COPENHAGEN, Denmark, Dec. 10, 2025 /PRNewswire/ -- CathVision, a medical technology company dedicated to improving clinical outcomes in cardiac electrophysiology through high-fidelity signal acquisition and intelligent software, today announced two major milestones: the appointment of Eric Thepaut as independent Chairman of the Board, and the commercial release of Version 3.5 of the ECGenius® System. Eric Thepaut Appointed Independent Chairman of the Board Eric Thepaut joins CathVision following his recent retirement from Boston Scientific Corporation (NYSE:BSX), where he serv

    12/10/25 4:00:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    CVS Health Updates Financial Guidance, Highlights Strength of Businesses, and Announces Strategy to Uniquely Reimagine Health Care at Investor Day Event

    Outlines strategy to deliver best-in-class execution, transform consumer experiences, be the partner of choice, and harness unique enterprise capabilities Updates 2025 full-year financial guidance; provides 2026 full-year financial guidance Commits to mid-teens Adjusted EPS CAGR through 2028 Announces strategy to uniquely reimagine health care through improved engagement and simplified experiencesHARTFORD, Conn., Dec. 9, 2025 /PRNewswire/ -- Today at its 2025 Investor Day, CVS Health® (NYSE:CVS) (the "Company") will launch its strategy to deliver best-in-class execution, transform consumer experiences, be the partner of choice, and harness unique enterprise capabilities to address challenges

    12/9/25 6:30:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health generates over $474 Billion in 2024 U.S. economic impact, supporting communities throughout the United States

    New report highlights the company's role as a top U.S. employer, investing in improving health and supporting local communities WOONSOCKET, R.I., Dec. 5, 2025 /PRNewswire/ -- CVS Health® (NYSE: CVS) today released its inaugural National Economic Impact Report demonstrating the positive economic impact that the company has in communities across the country. The report demonstrates how CVS Health delivers $474 billion annually for the U.S. economy and supports 1.3 million jobs nationwide through its operations in every U.S. state and Washington, D.C. In addition, CVS Health oper

    12/5/25 9:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $BSX
    $CVS
    SEC Filings

    View All

    CVS Health Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CVS HEALTH Corp (0000064803) (Filer)

    12/9/25 6:33:11 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form 8-K filed by CVS Health Corporation

    8-K - CVS HEALTH Corp (0000064803) (Filer)

    11/20/25 4:18:11 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Boston Scientific Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)

    11/19/25 4:20:18 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    $CVS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 1, 2024 - FDA Roundup: March 1, 2024

    For Immediate Release: March 01, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a letter of enforcement discretion for certain qualified health claims regarding the consumption of yogurt and the reduced risk of type 2 diabetes. The letter states that the FDA does not intend to object to the use of these claims, provide

    3/1/24 4:00:21 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    $CVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $BSX
    $CVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider O'Connor Padraig Andrew claimed ownership of 3,885 shares (SEC Form 3)

    3 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

    12/8/25 4:49:37 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    SVP, Cont & Chief Acct Officer Clark James David covered exercise/tax liability with 220 shares, decreasing direct ownership by 0.89% to 24,401 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    12/2/25 6:03:33 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    EVP, Chief Exp & Tech Officer Mandadi Tilak covered exercise/tax liability with 6,575 shares, decreasing direct ownership by 8% to 74,085 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    12/2/25 5:52:02 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    EVP and Chief People Officer Capozzi Heidi B bought $4,589 worth of shares (80 units at $57.36) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    10/14/25 7:08:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Director Sansone Guy P bought $100,009 worth of shares (1,570 units at $63.70), increasing direct ownership by 15% to 12,007 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    6/9/25 8:22:46 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Director Mahoney Michael F bought $2,001,000 worth of shares (30,000 units at $66.70), increasing direct ownership by 321% to 39,356 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    2/19/25 12:35:35 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $BSX
    $CVS
    Leadership Updates

    Live Leadership Updates

    View All

    CathVision Announces Appointment of Eric Thepaut as Independent Chairman of the Board and Releases ECGenius® System Version 3.5

    COPENHAGEN, Denmark, Dec. 10, 2025 /PRNewswire/ -- CathVision, a medical technology company dedicated to improving clinical outcomes in cardiac electrophysiology through high-fidelity signal acquisition and intelligent software, today announced two major milestones: the appointment of Eric Thepaut as independent Chairman of the Board, and the commercial release of Version 3.5 of the ECGenius® System. Eric Thepaut Appointed Independent Chairman of the Board Eric Thepaut joins CathVision following his recent retirement from Boston Scientific Corporation (NYSE:BSX), where he serv

    12/10/25 4:00:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    CVS Health Helps Improve Access to More Affordable Fertility Treatments

    WOONSOCKET, R.I., Oct. 16, 2025 /PRNewswire/ -- CVS Health (NYSE:CVS) today announced it will support simpler access to more affordable fertility treatments for all Americans through its CVS Specialty Pharmacy and make it easier to pick up fertility medication at its 9,000 community pharmacy locations. CVS Specialty Pharmacy will be a core partner in the TrumpRx Fertility program. As the Trump Administration continues to establish more competitive prices for important medicines, the Administration has engaged with EMD Serono, manufacturer of Gonal-F an in-vitro fertilization (

    10/16/25 5:09:00 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Aetna 2026 Medicare Advantage plans deliver access to affordable, personalized care

    Providing access to affordable care $0 copays on Tier 1 drugs & covered vaccines at in-network pharmacies1, $0 copay for colonoscopies and mammograms at in-network providers$0 copay for annual Healthy Home Visit from a licensed Signify Health clinicianContinued investment in technology, tools and teams that support our members Commitment to supporting unique member needs — those living with chronic conditions and individuals dually eligible for both Medicare and MedicaidLeveraging the strength of the CVS Health family of companies to deliver differentiated member experiencesWOONSOCKET, R.I., Oct. 1, 2025 /PRNewswire/ -- Aetna®, a CVS Health® company (NYSE: CVS), today announced our 2026 Medi

    10/1/25 7:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $BSX
    $CVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by CVS Health Corporation

    SC 13G - CVS HEALTH Corp (0000064803) (Subject)

    11/13/24 1:00:57 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form SC 13G/A filed by CVS Health Corporation (Amendment)

    SC 13G/A - CVS HEALTH Corp (0000064803) (Subject)

    2/13/24 5:02:40 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form SC 13G/A filed by Boston Scientific Corporation (Amendment)

    SC 13G/A - BOSTON SCIENTIFIC CORP (0000885725) (Subject)

    2/13/24 5:00:46 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    $CVS
    Financials

    Live finance-specific insights

    View All

    CVS HEALTH CORPORATION REPORTS THIRD QUARTER 2025 RESULTS AND UPDATES FULL-YEAR 2025 GUIDANCE

    Financial Highlights Third quarter total revenues increased to a record high $102.9 billion, up 7.8% compared to prior yearThird quarter GAAP diluted loss per share of $3.13, inclusive of a $5.7 billion goodwill impairment charge related to the Health Care Delivery reporting unitThird quarter Adjusted EPS of $1.60Generated year-to-date cash flow from operations of $7.2 billionOperational Highlights Aetna® receives industry-leading Medicare Advantage Star Ratings resultsLaunch of annual vaccination campaign at CVS Pharmacy® and MinuteClinic® locations nationwideCaremark® closes out another strong selling season with contract wins totaling nearly $6.0 billion and retention in the high nineties

    10/29/25 6:30:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Boston Scientific announces results for third quarter 2025

    MARLBOROUGH, Mass., Oct. 22, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.065 billion during the third quarter of 2025, growing 20.3 percent on a reported basis, 19.4 percent on an operational1 basis and 15.3 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $755 million or $0.51 per share (EPS), compared to $469 million or $0.32 per share a year ago, and achieved adjusted3 EPS of $0.75 for the period, compared to $0.63 a year ago.

    10/22/25 6:30:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    CVS Pharmacy completes acquisition of Rite Aid assets nationwide

    Company wraps up conversion of 63 former Rite Aid and Bartell Drugs stores in the Pacific Northwest and hundreds of prescription file buys across 15 states WOONSOCKET, R.I., Oct. 15, 2025 /PRNewswire/ -- CVS Pharmacy today announced the completion of its acquisition of select Rite Aid assets nationwide. In total, the company acquired and is now operating 63 former Rite Aid and Bartell Drugs stores in Idaho, Oregon and Washington. CVS Pharmacy also acquired the prescription files of 626 former Rite Aid and Bartell Drugs pharmacies in 15 states. As a result of the transactions, CVS Pharmacy is pleased to be serving more than nine million former Rite Aid and Bartell Drugs patients.

    10/15/25 8:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples